JP5501352B2 - 置換ピリミド[2,1−a]イソキノリン−4−オン誘導体 - Google Patents
置換ピリミド[2,1−a]イソキノリン−4−オン誘導体 Download PDFInfo
- Publication number
- JP5501352B2 JP5501352B2 JP2011515666A JP2011515666A JP5501352B2 JP 5501352 B2 JP5501352 B2 JP 5501352B2 JP 2011515666 A JP2011515666 A JP 2011515666A JP 2011515666 A JP2011515666 A JP 2011515666A JP 5501352 B2 JP5501352 B2 JP 5501352B2
- Authority
- JP
- Japan
- Prior art keywords
- isoquinolin
- pyrimido
- pyridin
- hydrogen atom
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C[C@](*)(C(*)c(c(*)c(*)c(*)c1*)c1C1=NC(*)=C2*)N1C2=O Chemical compound C[C@](*)(C(*)c(c(*)c(*)c(*)c1*)c1C1=NC(*)=C2*)N1C2=O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
- A01N43/54—1,3-Diazines; Hydrogenated 1,3-diazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
Description
R1は、4−ピリジン環または4−ピリミジン環を表し;
R2は、水素原子を表し;
R3は、水素原子を表し;
R4は、水素原子またはハロゲン原子を表し;
R7、R8、R9、R10は、互いに独立に、水素原子、ハロゲン原子、C1−6アルコキシ基、ニトロ、ヒドロキシル、またはアミノを表し;
R1は、4−ピリジン環または4−ピリミジン環を表し;
R2は、水素原子を表し;
R3は、水素原子を表し;
R4は、水素原子を表し;
R7、R8、R9、R10は、互いに独立に、水素原子、ハロゲン原子、C1−6アルコキシ基、ニトロ、ヒドロキシル、またはアミノを表し;
および表1の化合物
1.2−ピリジン−4−イル−ピリミド[2,1−a]イソキノリン−4−オン
2.10−ブロモ−2−ピリジン−4−イル−ピリミド[2,1−a]イソキノリン−4−オン
3.10−メトキシ−2−ピリジン−4−イル−ピリミド[2,1−a]イソキノリン−4−オン
4.8−ニトロ−2−ピリジン−4−イル−ピリミド[2,1−a]イソキノリン−4−オン
5.8−アミノ−2−ピリジン−4−イル−ピリミド[2,1−a]イソキノリン−4−オン
6.10−ヒドロキシ−2−ピリジン−4−イル−ピリミド[2,1−a]イソキノリン−4−オン
7.10−メトキシ−2−ピリミジン−4−イル−ピリミド[2,1−a]イソキノリン−4−オン
8.2−ピリジン−4−イル−6,7−ジヒドロ−ピリミド[2,1−a]イソキノリン−4−オン
9.9,10−ジメトキシ−2−ピリジン−4−イル−6,7−ジヒドロ−ピリミド[2,1−a]イソキノリン−4−オン
さらなる目的として、本発明はまた、前述の式(I)によって表されるピリミドン化合物を調製するための方法にも関する。
調製方法:
前述の式(I)によって表されるピリミドン化合物は、スキーム1に記載されている方法に従って調製することができる。
10−ブロモ−2−ピリジン−4−イル−4H−ピリミド[2,1−a]イソキノリン−4−オンショウ酸塩(1:1)
7−ブロモイソキノリン−1−アミン(WO9847876に記載されている合成)0.1g(0.38mmol)および3−(4−ピリジニル)−3−オキソプロピオン酸エチル0.134g(0.69mmol)の混合物に、酢酸アンモニウム0.059g(0.77mmol)を加えた。反応混合物を140℃で12時間加熱した。次いで、Dowtherm Aを2ml加え、得られた混合物を210℃で8時間撹拌させた。冷却後、水を加え、得られた溶液を6N塩酸イソプロパノールを用いて酸性化させた。Dowtherm Aをジエチルエーテルを用いて抽出し、水相を水酸化ナトリウム(30%)の水溶液によって塩基性化し、ジクロロメタンで抽出した。抽出物を硫酸ナトリウムで乾燥し、蒸発させた。得られた残留物を99/1から95/5の割合のジクロロメタン/メタノール混合物を溶離液とするシリカゲルのクロマトグラフィーによって精製して、通常の方式でシュウ酸塩に転換した所望の化合物0.041g(30%)を得て、固形物として純粋な生成物を得た。
Mp:244−246℃
RMN 1H(DMSO−d6;200MHz)
δ(ppm):9.25(s,1H)、8.80(d,2H)、8.70(d,1H)、8.30(d,2H)、8.10(dd,1H)、8.00(dd,1H)、7.65(d,1H)、7.40(s,1H)。
10−メトキシ−2−ピリジン−4−イル−4H−ピリミド[2,1−a]イソキノリン−4−オンマレイン酸塩(1:1)
実施例1に記載した方法と類似した方法によって、7−ブロモイソキノリン−1−アミンの代わりに7−メトキシイソキノリン−1−アミン(WO9847876に記載されている合成)を用いて、生成物を得、これを通常の方式でマレイン酸塩に転換して固形物0.22g(16%)を得た。
Mp:260−262℃
RMN 1H(DMSO−d6;200MHz)
δ(ppm):9.20(d,2H)、9.00(d,2H)、8.75(d,1H)、8.55(d,1H)、8.00(d,1H)、7.60(m,3H)、4.00(s,3H)。
2−ピリジン−4−イル−6,7−ジヒドロ−ピリミド[2,1−a]イソキノリン−4−オンショウ酸塩(1:1)
4.1 2−ピリジン−4−イル−ピリミド[2,1−a]イソキノリン−4−オン
実施例1に記載した方法と類似した方法によって、7−ブロモイソキノリン−1−アミンの代わりにイソキノリン−1−アミン(WO9847876に記載されている合成)を用いて、遊離塩基として生成物を得て、固形物1.0g(13%)を得、これはそのまま次のステップに使用された。
2−ピリジン−4−イル−ピリミド[2,1−a]イソキノリン−4−オン0.20g(0.73mmol)のメタノール15ml中溶液に、塩酸のイソプロパノール中6N溶液0.500mlおよびパラジウム炭素触媒0.05g(10%重量/重量)を加えた。
Mp:255−257℃
RMN 1H(DMSO−d6;200MHz)
δ(ppm):8.80(br s,2H)、8.50(d,1H)、8.15(d,2H)、7.80−7.40(m,3H)、7.15(s,1H)、4.20(dd,2H)、3.10(dd,2H)。
4つの異なるプロトコールを用いることができる。
(1)錠剤
以下の成分を、通常の方法によって混合し、従来の装置を用いて圧縮した。
実施例1の化合物 30mg
結晶セルロース 60mg
トウモロコシデンプン 100mg
乳糖 200mg
ステアリン酸マグネシウム 4mg
(2)軟カプセル剤
以下の成分を、通常の方法によって混合し、軟カプセル剤に充填した。
実施例1の化合物 30mg
オリーブ油 300mg
レシチン 20mg
(3)非経口製剤
以下の成分を、通常の方法によって混合して、アンプル1ml中に含まれる注射剤を調製した。
実施例1の化合物 3mg
塩化ナトリウム 4mg
注射用蒸留水 1ml
Claims (14)
- 2−ピリジン−4−イル−ピリミド[2,1−a]イソキノリン−4−オン
10−ブロモ−2−ピリジン−4−イル−ピリミド[2,1−a]イソキノリン−4−オン
10−メトキシ−2−ピリジン−4−イル−ピリミド[2,1−a]イソキノリン−4−オン
8−ニトロ−2−ピリジン−4−イル−ピリミド[2,1−a]イソキノリン−4−オン
8−アミノ−2−ピリジン−4−イル−ピリミド[2,1−a]イソキノリン−4−オン
10−ヒドロキシ−2−ピリジン−4−イル−ピリミド[2,1−a]イソキノリン−4−オン
10−メトキシ−2−ピリミジン−4−イル−ピリミド[2,1−a]イソキノリン−4−オン
2−ピリジン−4−イル−6,7−ジヒドロ−ピリミド[2,1−a]イソキノリン−4−オン
9,10−ジメトキシ−2−ピリジン−4−イル−6,7−ジヒドロ−ピリミド[2,1−a]イソキノリン−4−オン
からなる群から選択される、請求項1および2に記載の、ピリミドイソキノリン誘導体またはこれらの塩、またはこれらの溶媒和物またはこれらの水和物。 - 請求項1から3に記載の、式(I)によって表されるピリミドン誘導体またはこれらの塩、またはこれらの溶媒和物またはこれらの水和物からなる群から選択される物質を有効成分として含む医薬品。
- 請求項1から3に記載の、式(I)によって表されるピリミドン誘導体またはこれらの塩の群から選択される、GSK3β阻害剤。
- 神経変性疾患の予防的および/または治療的処置のための、請求項1から3に記載の化合物。
- 神経変性疾患がアルツハイマー病、パーキンソン病、タウオパシー、血管性認知症;急性脳卒中、外傷;脳血管発作、脳外傷、脊髄外傷;末梢神経障害;網膜症または緑内障からなる群から選択される、請求項6に記載の化合物。
- インスリン非依存性糖尿病;肥満症;躁うつ病;統合失調症;脱毛症;癌;実質性腎疾患または筋萎縮症の予防的および/または治療的処置のための、請求項1から3に記載の化合物。
- 癌が乳癌、非小細胞肺癌、甲状腺癌、TもしくはB細胞白血病またはウイルス誘導腫瘍である、請求項8に記載の化合物。
- マラリアの予防的および/または治療的処置のための、請求項1から3に記載の化合物。
- 骨疾患の予防的および/または治療的処置のための、請求項1から3に記載の化合物。
- 尋常性天疱瘡の予防的および/または治療的処置のための、請求項1から3に記載の化合物。
- 癌の化学療法によって誘発される好中球減少症の予防的および/または治療的処置のための、請求項1から3に記載の化合物。
- 失認および記憶欠損を特徴とする疾患の治療的処置のための、請求項1から4に記載の化合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08290618.1 | 2008-06-26 | ||
EP08290618A EP2138495A1 (en) | 2008-06-26 | 2008-06-26 | Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives |
PCT/IB2009/006460 WO2009156859A1 (en) | 2008-06-26 | 2009-06-25 | Substituted pyrimido [2, 1-a] isoquinolin-4-one derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011525904A JP2011525904A (ja) | 2011-09-29 |
JP5501352B2 true JP5501352B2 (ja) | 2014-05-21 |
Family
ID=39971001
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011515666A Expired - Fee Related JP5501352B2 (ja) | 2008-06-26 | 2009-06-25 | 置換ピリミド[2,1−a]イソキノリン−4−オン誘導体 |
Country Status (16)
Country | Link |
---|---|
US (1) | US8211903B2 (ja) |
EP (2) | EP2138495A1 (ja) |
JP (1) | JP5501352B2 (ja) |
KR (1) | KR20110027803A (ja) |
CN (1) | CN102076683A (ja) |
AR (1) | AR072228A1 (ja) |
AU (1) | AU2009263845A1 (ja) |
BR (1) | BRPI0914665A2 (ja) |
CA (1) | CA2728693A1 (ja) |
EA (1) | EA201170094A1 (ja) |
IL (1) | IL210171A0 (ja) |
MX (1) | MX2010013941A (ja) |
NZ (1) | NZ590045A (ja) |
TW (1) | TW201014854A (ja) |
WO (1) | WO2009156859A1 (ja) |
ZA (1) | ZA201009270B (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2138493A1 (en) * | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidone derivatives |
EP2138485A1 (en) * | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted N-Oxide pyrazine derivatives |
EP2138494A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted alkyl pyrimidin-4-one derivatives |
EP2138488A1 (en) * | 2008-06-26 | 2009-12-30 | sanofi-aventis | 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases |
EP2138492A1 (en) * | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidin-4-one derivatives |
EP2138498A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted tricyclic derivatives against neurodegenerative diseases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5170780A (ja) | 1974-12-17 | 1976-06-18 | Nippon Shinyaku Co Ltd | Shinkinabenzoguanidoruino seiho |
EG13192A (en) | 1976-02-10 | 1982-12-31 | Rhone Poulenc Ind | Nouveaux derives du dithiole-1,2 leur preparation et les compositions qui les contiennent |
HU178496B (en) | 1977-12-29 | 1982-05-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing 6,7,8,9-tetrahydro-4h-pyrido/1,2-a/pyrimidine derivatives with antiallergic activity |
US4406897A (en) | 1981-07-06 | 1983-09-27 | William H. Rorer, Inc. | 6-Aryl-4-hydrazinyl-s-triazin-2-ones |
US4804663A (en) | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
US5629322A (en) | 1994-11-15 | 1997-05-13 | Merck & Co., Inc. | Cyclic amidine analogs as inhibitors of nitric oxide synthase |
AU700078B2 (en) | 1995-11-01 | 1998-12-17 | Merck & Co., Inc. | Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases |
IL123986A (en) | 1997-04-24 | 2011-10-31 | Organon Nv | Medicinal compounds |
CA2368413C (en) * | 1999-03-31 | 2008-07-29 | Vernalis Limited | Derivatives of pyrimido[6,1-a]isoquinolin-4-one |
EP1136484A1 (en) | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-(Arylalkylamino)pyrimidone derivatives |
WO2002087589A1 (fr) | 2001-04-26 | 2002-11-07 | Daiichi Pharmaceutical Co., Ltd. | Medicament permettant d'inhiber une pompe d'elimination de medicament |
EP1430056B1 (en) | 2001-09-21 | 2005-10-26 | Sanofi-Aventis | Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders |
CA2495661C (en) | 2002-08-16 | 2011-06-14 | Kinacia Pty Ltd. | Inhibition of phosphoinositide 3-kinase beta |
EP1454909B1 (en) * | 2003-03-07 | 2008-08-20 | Sanofi Aventis | 8'-pyridinyl-dihydrospiro (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro (cycloalkyl) pyrimido (1,2-a) pyrimidin-6 derivatives -one and their use against neurodegenerative diseases |
EP1460076A1 (en) | 2003-03-21 | 2004-09-22 | Sanofi-Synthelabo | Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives |
EP1790649A1 (en) * | 2005-11-21 | 2007-05-30 | Sanofi-Aventis | Substituted bicyclic pyrimidone derivatives |
EP2138493A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidone derivatives |
EP2138488A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases |
EP2138494A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted alkyl pyrimidin-4-one derivatives |
EP2138492A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidin-4-one derivatives |
EP2138485A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted N-Oxide pyrazine derivatives |
-
2008
- 2008-06-26 EP EP08290618A patent/EP2138495A1/en not_active Withdrawn
-
2009
- 2009-06-24 AR ARP090102316A patent/AR072228A1/es unknown
- 2009-06-24 TW TW098121232A patent/TW201014854A/zh unknown
- 2009-06-25 KR KR1020117001901A patent/KR20110027803A/ko not_active Application Discontinuation
- 2009-06-25 CA CA2728693A patent/CA2728693A1/en not_active Abandoned
- 2009-06-25 AU AU2009263845A patent/AU2009263845A1/en not_active Abandoned
- 2009-06-25 CN CN200980124554XA patent/CN102076683A/zh active Pending
- 2009-06-25 BR BRPI0914665A patent/BRPI0914665A2/pt not_active IP Right Cessation
- 2009-06-25 EA EA201170094A patent/EA201170094A1/ru unknown
- 2009-06-25 JP JP2011515666A patent/JP5501352B2/ja not_active Expired - Fee Related
- 2009-06-25 MX MX2010013941A patent/MX2010013941A/es not_active Application Discontinuation
- 2009-06-25 EP EP09769670.2A patent/EP2321313B1/en active Active
- 2009-06-25 NZ NZ590045A patent/NZ590045A/en not_active IP Right Cessation
- 2009-06-25 WO PCT/IB2009/006460 patent/WO2009156859A1/en active Application Filing
-
2010
- 2010-12-15 US US12/968,950 patent/US8211903B2/en not_active Expired - Fee Related
- 2010-12-22 IL IL210171A patent/IL210171A0/en unknown
- 2010-12-23 ZA ZA2010/09270A patent/ZA201009270B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2321313B1 (en) | 2015-09-02 |
KR20110027803A (ko) | 2011-03-16 |
ZA201009270B (en) | 2012-03-28 |
US20110144138A1 (en) | 2011-06-16 |
NZ590045A (en) | 2011-11-25 |
IL210171A0 (en) | 2011-03-31 |
US8211903B2 (en) | 2012-07-03 |
WO2009156859A1 (en) | 2009-12-30 |
EP2138495A1 (en) | 2009-12-30 |
EA201170094A1 (ru) | 2011-08-30 |
AU2009263845A1 (en) | 2009-12-30 |
CA2728693A1 (en) | 2009-12-30 |
BRPI0914665A2 (pt) | 2015-10-20 |
JP2011525904A (ja) | 2011-09-29 |
TW201014854A (en) | 2010-04-16 |
MX2010013941A (es) | 2011-06-24 |
CN102076683A (zh) | 2011-05-25 |
AR072228A1 (es) | 2010-08-11 |
EP2321313A1 (en) | 2011-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5501352B2 (ja) | 置換ピリミド[2,1−a]イソキノリン−4−オン誘導体 | |
JP5501353B2 (ja) | 置換されたピリミドン誘導体 | |
JP5409783B2 (ja) | 置換n−オキシドピラジン誘導体 | |
JP5581318B2 (ja) | 神経変性疾患治療用のgsk3−ベータ阻害剤としての4−(ピリジン−4−イル)−1h−(1,3,5)トリアジン−2−オン誘導体 | |
JP5501355B2 (ja) | 置換アルキルピリミジン−4−オン誘導体 | |
JP5124471B2 (ja) | 置換二環式ピリミドン誘導体 | |
JP5508257B2 (ja) | アリールアミドピリミドン化合物 | |
JP5509070B2 (ja) | 神経変性疾患の治療のためのアリールアミドピリミドン誘導体 | |
BRPI0718519A2 (pt) | 8-piperidinil-2-pridinil-pirimido-[1,2-a]piridimin-6-ona substituída e derivados da 8-piperidinil-2-pirimidinil-pirimido[1,2-a]pirimidin-6-ona | |
JP5501354B2 (ja) | 神経変性疾患に対する置換三環式誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120425 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131015 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140114 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140210 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140311 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5501352 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |